Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern

• DOI: 10.1038/s41467-022-29477-0
• Publication Date: 2022-04-04T10:04:51Z
• Authors: Xiaoqi Yu; Dong Wei; Wenxin Xu; Chuanmiao Liu; Wentian Guo; Xinxin Li; Wei Tan; Leshan Liu; Xinxin Zhang; Jieming Qu; Zhitao Yang; Erzhen Chen
• Keywords: Pandemic

Abstract The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the generation variants that may diminish host immune responses to vaccine formulations. Here we show a registered observational clinical trial (NCT04795414), assess safety and immunogenicity inactivated SARS-CoV-2 BBIBP-CorV cohort 1006 recipients. No serious adverse events are observed during term study. Detectable virus-specific antibody is measured determined be neutralizing 698/760 (91.84%) recipients on day 28 post second dose 220/581 (37.87%) 180 dose, whereas vaccine-elicited sera varying degrees reduction neutralization against range key variants, including variant Alpha, Beta, Gamma, Iota, Delta. Our work diminished potency multiple sera, which indicates potential need for additional boost vaccinations.